Partner With Us to Advance Kidney Care
Consun Pharmaceutical brings proven commercial scale in China's nephrology market, a next-generation R&D engine, and a globalized BD team — creating a uniquely compelling platform for partners seeking to develop and commercialize kidney disease therapies.
Partnerships Built on Shared Vision
We seek collaborations that are mutually beneficial and sustained by a shared commitment to improving outcomes for kidney disease patients worldwide.
At Consun, partnering is integral to our innovation strategy. As China's nephrology leader, we bring deep therapeutic expertise, established commercial infrastructure covering over 90% of top nephrology departments, and a patient population of over 3 million — offering partners an unparalleled pathway to the world's largest kidney disease market.
Our business development team, composed of professionals with backgrounds at leading multinational pharmaceutical companies including Pfizer, Merck, AstraZeneca, and Novartis, works as a highly integrated unit across search & evaluation, deal structuring, and post-deal alliance management to ensure each partnership delivers on its potential.
From early discovery collaborations through late-stage licensing and commercialization agreements, we are structured to move quickly and commit fully. Every partnership is sponsored at the senior leadership level, ensuring strategic alignment and resource commitment from day one.
What We Bring to Partnerships
A comprehensive platform purpose-built for nephrology success in China and beyond.
How We Work With Partners
We offer flexible partnership structures tailored to each opportunity — from early research alliances to full commercialization agreements.
Where We Focus Our Partnering Efforts
Our core therapeutic expertise guides where we believe we can create the most value for partners and patients.
As China's leading nephrology-focused pharmaceutical company, we are deeply committed to advancing the standard of care in kidney disease. Our commercial, clinical, and regulatory capabilities in this space are unmatched.
- Innovative therapies for CKD, including novel mechanisms of action
- Treatments for dialysis complications and kidney transplant support
- Renoprotective agents and combination approaches
- Diagnostic and biomarker technologies for kidney disease
- Digital health solutions for nephrology patient management
A growing therapeutic area with established hospital-based commercial infrastructure covering 5,000+ hospitals and a dedicated physician network.
- Differentiated products for women's health indications
- Pediatric formulations and novel delivery systems
- Late-stage or approved assets for in-licensing
A specialized portfolio of diagnostic imaging contrast agents with strong market positioning and top 3 market share in key product categories.
- Next-generation contrast agents for MRI, CT, and ultrasound
- Molecular imaging and targeted contrast technologies
- AI-enhanced diagnostic imaging solutions
Flexible, Responsive, Committed
Our BD team evaluates opportunities across the full development continuum — from early discovery through commercialized products. We are structured for rapid decision-making, with clear governance pathways that allow us to move from initial evaluation to term sheet within weeks, not months.
We prioritize opportunities where Consun's deep nephrology expertise and commercial reach create differentiated value — and where our capabilities meaningfully accelerate a partner's program toward patients.
Upcoming Conferences & Events
Let's Explore What We Can Build Together
Whether you have an innovative asset in nephrology, a platform technology, or a commercialization opportunity in China — our BD team is ready to discuss how Consun can be your partner-of-choice.
Please do not include confidential information in initial submissions. All inquiries are reviewed by our BD team and handled with discretion.